424.25MMarket Cap-5587P/E (TTM)
10.070High8.805Low298.55KVolume9.020Open8.900Pre Close2.86MTurnover1.79%Turnover RatioLossP/E (Static)43.12MShares35.06052wk High1.18P/B164.08MFloat Cap6.75052wk Low--Dividend TTM16.68MShs Float35.060Historical High--Div YieldTTM14.21%Amplitude6.750Historical Low9.573Avg Price1Lot Size
Kyverna Therapeutics Stock Forum
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet